Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

5-6 Cardiovascular Pharmacotherapeutics
Adrenergic receptor blockade as a therapeutic
approach for suppressing the renin-angiotensinaldosterone
system in normotensive and hypertensive
subjects. Am J Hypertens 12:451, 1999.
141. Myers MG, Lewis PJ, Reid JL, Dollery CT: Brain
concentration of propranolol in relation to hypotension
effects in the rabbit with observations on
brain propranolol levels in man. J Pharmacol Exp
Ther 192:327, 1975.
142. Prichard BNC: Propranolol as an antihypertensive
agent. Am Heart J 79:128-133, 1979.
143. Imhof PR: Characterization of beta-blockers as
antihypertensive agents in the light of human
pharmacology studies, In: Schweizer W, ed. Beta-
Blockers—Present Status and Future Prospects.
Bern: Huber, l974:40-50.
144. Langer SZ: Presynaptic receptors and their role in
the regulation of transmitter release. Br J Pharmacol
60:481, 1977.
145. Berthelsen S, Pettinger WA: A functional basis for
classification of b-adrenergic receptors. Life Sci
2l:595, 1977.
146. Yamaguchi N, de Champlain J, Nadeau RL: Regulation
of norepinephrine release from cardiac sympathetic
fibers in the dog by presynaptic a- and
b-receptors. Circ Res 41:108, 1976.
147. Stjarne L, Brundin J: b-Adrenoceptors facilitate
noradrenaline secretion from human vasoconstrictor
nerves. Acta Physiol Scand 97:88, 1976.
148. Majewski HJ, McCulloch MW, Rand MJ, Story DF:
Adrenaline activation of prejunctional b-adrenoceptors
in guinea pig atria. Br J Pharmacol 71:435,
1980.
149. Savolainen A, Keto P, Poutanen V-P, et al: Effects of
angiotensin converting enzyme inhibition versus
b-adrenergic blockade on aortic stiffness in essential
hypertension. J Cardiovasc Pharmacol 27:99,
1996.
150. Waal HJ: Hypotensive action of propranolol. Clin
Pharmacol Ther 7:588-598, 1966.
151. Rahn KH, Hawlina A, Kersting F, Peanz G: Studies
on the antihypertensive action of the optical
isomers of propranolol in man. Naunyn Schmiedebergs
Arch Pharmacol 286:319-, 1974.
152. Pickering TG, Gribbin B, Petersen ES, et al: Effects
of autonomic blockade on the baroreflex in man at
rest and during exercise. Circ Res 30:177, 1972.
153. Kato N, Sugiyama T, Morita H, et al: Association
analysis of beta 2 -adrenergic receptor polymorphisms
with hypertension in Japanese. Hypertension
37:286, 2001.
154. Bray MS, Krushkal J, Li L, et al: Positional genomic
analysis identifies the beta 2 -adrenergic receptor
gene as a susceptibility locus for human hyperten-
sion. Circulation 101:2877, 2000.
155. Bengtsson K, Melander O, Orho-Melander M, et
al: Polymorphism in the beta 1 -adrenergic receptor
gene and hypertension. Circulation 104:187, 2001.
156. Jia H, Hingorani AD, Sharma P, et al: Association
of the G s α gene with essential hypertension and response
to b blockade. Hypertension 34:8, 1999.
157. Sonnenblick EH, Ross J Jr, Braunwald E: Oxygen
consumption of the heart: newer concepts of its
multifactorial determination. Am J Cardiol 22:328-
336, 1968.
158. Sonnenblick EH, Skelton CL: Myocardial energetics:
basic principles and clinical implications. N
Engl J Med 285:668-675, 1971.
159. Black JW, Stephenson JS: Pharmacology of a new
adrenergic beta-receptor blocking compound
(Nethalide). Lancet 2:311-314, 1962.
160. Frishman WH: Beta-adrenergic blockade in the
treatment of coronary artery disease. In: Hurst JW,
ed. Clinical Essays on the Heart, Vol 2. New York:
McGraw-Hill, l983:25.
161. Billinger M, Seiler C, Fleisch M, et al: Do betaadrenergic
blocking agents increase coronary flow
reserve? J Am Coll Cardiol 38:1866, 2001.
162. Frishman WH, Gabor R, Pepine C, Cavusoglu E:
Heart rate reduction in the treatment of chronic
stable angina pectoris: experience with a sinus
node inhibitor. Am Heart J 131:204, 1996.
163. Brouwer J, Viersma JW, van Veldhuisen DJ, et al:
Usefulness of heart rate variability in predicting
drug efficacy (metoprolol vs diltiazem) in patients
with stable angina pectoris. Am J Cardiol 76:759,
1995.
164. Ardissino D, Savonitto S, Egstrup K, et al: Selection
of medical treatment in stable angina pectoris:
results of the International Multicenter Angina Exercise
(IMAGE) study. J Am Coll Cardiol 25:1516,
1995.
165. Frishman W, Pepine CJ, Weiss R, Baiker WM for
the Zatebradine Study Group: Addition of zatebradine,
a direct sinus node inhibitor, provides no
greater exercise tolerance benef\hskip.1ptit in patients
with angina pectoris taking extended-release
nifedipine: results of a multicenter, randomized,
double-blind, placebo-controlled, parallel group
study. J Am Coll Cardiol 26:305, 1995.
166. Parratt JR, Grayson J: Myocardial vascular reactivity
after b-adrenergic blockade. Lancet 1:338-340,
1966.
167. Becker LC, Fortuin NJ, Pitt B: Effects of ischemia
and anti-anginal drugs on the distribution of radioactive
microspheres in the canine left ventricle.
Circ Res 28:263-269, 1971.
168. Wolfson S, Gorlin R: Cardiovascular pharmacolo-